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ABSTRACT Ionotropic glutamate receptors (iGluRs), a family of ligand-gated ion channels, are responsible for the majority of
fast excitatory neurotransmission in the central nervous system. Within this family, different members serve distinct roles at
glutamatergic synapses. Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors mediate fast depolarization while
N-methyl-D-aspartate (NMDA) receptors mediate the slower component of the excitatory postsynaptic potential. These dispa-
rate functions suggest alternate modes of regulation. In this work, we show that endogenous regulators of iGluRs have different
abilities to bind to speciﬁc domains of NMDA NR1-1b and AMPA GluR2 subunits. We have previously shown that the sulfated
neurosteroids pregnenolone sulfate and 3a-hydroxy-5b-pregnan-20-one sulfate bind to the extracellular glutamate-binding core
(S1S2) of the GluR2 subunit. Here we show that neither neurosteroid binds to the S1S2 domain of the NMDA NR1-1b subunit.
This NR1-1b NMDA domain does, however, bind to the endogenous polyamines spermine and spermidine as well as Zn(II).
Binding of the polyamines and Zn(II) to the S1S2 domain of the GluR2 subunit was not observed. This binding of Zn(II) and
polyamines to the S1S2 domain of the NR1-1b subunit deﬁnes a new binding site for each of these modulators.
INTRODUCTION
Ionotropic glutamate receptors (iGluRs) comprise a family of
ligand-gated ion channels that include the amino-3-hydroxy-
5-methyl-4-isoxazolepropionic acid (AMPA), kainate, and
N-methyl-D-aspartate (NMDA) receptors. These receptors are
located in the postsynaptic neural membrane and play impor-
tant roles in developmental plasticity, learning and memory,
sensory transmission and coordination, and control of respi-
ration and blood pressure. Binding of the neurotransmitter
glutamate (glycine is a coagonist for the NMDA receptors) to
an extracellular binding site on these receptors causes a con-
formational change which opens a pore, allowing cations to
ﬂow into the postsynaptic neural cell.
Each of the iGluRs is believed to be tetrameric in nature.
The NMDA receptors are hetero-tetramers composed of two
NR1 and two NR2 subunits. There are eight alternatively
spliced versions of the NR1 subunit, encoded by a single gene,
and four different NR2 subunits (NR2A–D) encoded by sepa-
rate genes. The non-NMDA receptors are most often homo-
tetramers. AMPA receptors are composed of four GluR1,
GluR2, GluR3, or GluR4 subunits while kainate receptors
are composed of four GluR5, GluR6, GluR7, KA1, or KA2
subunits. Each of these iGluR subunits has a similar modular
membrane-spanning topology. The extracellular portion of
each subunit has an amino terminal domain (ATD) and an S1
domain that precede the ﬁrst membrane-spanning region. In
addition, there is an extracellular S2 domain that separates
the second and third membrane spanning regions, three
membrane spanning domains, and a reentrant loop, the latter
of which forms the pore region upon association of all four
subunits. The extracellular S1 and S2 regions are known
to form a clamshell-shaped binding domain for the natural
agonist glutamate (in the non-NMDA receptors as well as in
the NR2 NMDA subunits) or glycine (in the NR1 NMDA
subunits). Soluble extracellular GluR2 (AMPA) and NR1-1b
(NMDA) S1S2 domains have been constructed by eliminat-
ing all three transmembrane spanning regions plus the reen-
trant loop and linking the S1 and S2 domains by two amino
acids (GT) (1–4). These S1S2 domains have been shown to
possess near-native binding afﬁnities for both agonists and
antagonists and their structures have been studied by x-ray
crystallography (Fig. 1) (1–4).
As glutamate is the major excitatory neurotransmitter in
the central nervous system, the level of activity of iGluRs
is tightly controlled. Misregulation has been implicated in
the ischemic stroke cascade, schizophrenia, and Alzheimer’s,
Huntington’s, and Parkinson’s diseases. A number of endog-
enous compounds, including Zn(II), polyamines (spermine
and spermidine, Fig. 2), and sulfated neurosteroids (preg-
nenolone sulfate, PS; and 3a-hydroxy-5b-pregnan-20-one
sulfate, PregaS, Fig. 2), are known to be involved in reg-
ulation.
PregaS negatively regulates the activity of all iGluRs. PS
also negatively regulates the activity of the non-NMDA
iGluRs, while differentially regulating the NMDA receptors.
It is the most active neurosteroid in its ability to positively
regulate NMDA receptors possessing either NR2A or B sub-
units (5), while it negatively regulates NMDA receptors with
either NR2C or D subunits. It has recently been shown that
both PS and PregaS bind to the S1S2 domain of the GluR2
subunit of the AMPA receptor (6,7). In addition, it has been
demonstrated that PS binds to the NR2B subunit of the
NMDA receptor in a region that encompasses portions of the
extracellular S2 domain and the ﬁnal transmembrane span-
ning region (8).
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Zn(II), which is stored and released at many glutamatergic
synapses in the brain, regulates the activity of iGluRs by many
different pathways, both voltage-dependent and -independent
(9,10). This regulation can either potentiate or block activity at
iGluRs, depending on the type of iGluR and the concentration
of Zn(II) (11). The existence of an NMDA high afﬁnity NR1/
NR2A Zn(II) inhibitory site as well as NR1/NR2B, NR1/
NR2C, and NR1/NR2D low afﬁnity Zn(II) inhibitory sites
have been reported (12–16). The NR2A and NR2B binding
sites have been suggested to reside in the extracellular ATD
of each subunit (10,17). It has, however, been shown that
both the NR1 and NR2 subunits contribute to Zn(II) inhibi-
tion (12,15,18), with the presence of exon 5 in the ATD of
the NR1 subunit (NR1a forms lack exon 5, while NR1b
forms include exon 5) playing a regulatory role.
The endogenous polyamines spermine and spermidine are
necessary for a number of cellular functions, including pro-
liferation and differentiation, stabilization of nucleic acids,
regulation of protein synthesis, and modulation of ion channel
functioning, including that of the iGluRs (19,20). At NMDA
receptors, they have been proposed to act by at least four
distinct mechanisms, including both glycine and voltage-
dependent and -independent mechanisms (19–24). Con-
centrations of glycine, polyamines, and the NMDA subunit
composition determine whether this action is activating or
inhibiting (21,25). Control of glycine-independent poten-
tiation has been suggested to occur via residues in both the
NR1a and NR2B subunits, including NR1a residues in
regions between the third and fourth membrane spanning
regions as well as amino acids in the ATD of both subunits
(21,26–28).
Thus, while sulfated neurosteroids, polyamines, and Zn(II)
do regulate the activities of both NMDA and non-NMDA
iGluRs, regulation is achieved in a complicated manner,
implicating binding at multiple sites, none of which are yet
fully elucidated. The results presented here further describe
the binding of each of these three classes of ligands to spe-
ciﬁc subunit domains from both NMDA (NR1-1b) and non-
NMDA (AMPA: GluR2) receptors. We have previously
shown that the sulfated neurosteroids PS and PregaS bind to
the GluR2 S1S2 domain (6,7). Data is presented here which
shows that neither PS nor PregaS bind to the S1S2 domain of
the NR1-1b subunit of the NMDA receptor. In addition, it
has been found that neither Zn(II) nor the polyamines spermine
or spermidine bind to the GluR2 S1S2 domain, however,
they do bind to the NMDA NR1-1b S1S2 domain. The latter
is signiﬁcant because it locates a previously unidentiﬁed
distinct subunit domain to which each of these modulatory
ligands bind.
MATERIALS AND METHODS
Protein expression and puriﬁcation of NMDA
NR1-1b S1S2 domain
The cloning plasmid for the NMDA NR1-1b S1S2 domain was obtained
from Eric Gouaux (Oregon Health and Science University, Portland, OR)
and transformed into chemically competent Escherichia coli Origami
FIGURE 1 (Left) RASMOL rendering of the apo GluR2
S1S2 domain (PDB: 1FTO) (1). The four tryptophan
residues in the S1S2 domain (Trp-460, -671, -766, and
-767) are space-ﬁlled and are shown in black. In addition,
the location of the glutamate (Glu) binding pocket is
illustrated. (Right) RASMOL rendering of the glycine
bound NMDA NR1-1b S1S2 domain (PDB: 1PB7) (4).
The four tryptophan residues in the S1S2 domain (Trp-
498, -731, -768, and -792) are space-ﬁlled and are shown
in black. In addition, the location of the glycine (Gly)
binding pocket is illustrated.
FIGURE 2 Endogenous ligand structures. (A) Pregnen-
olone sulfate (PS), (B) 3a-hydroxy-5b-pregnan-20-one
sulfate (PregaS), (C) spermine, and (D) spermidine.
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B(DE3) cells. The expression system was designed as follows: (His)8-TSG-
LVPRG(thrombin cut site)-S1(394-544)-GT-S2(663-800). NMDA NR1-1b
S1S2 protein was overexpressed and puriﬁed as in Furukawa et al. (4).
Protein expression and puriﬁcation of wt and
mutant AMPA GluR2 S1S2 domains
Mutant AMPA GluR2 S1S2 domains (amino acids: S1:383-524-GT-S2:
627-791) were constructed and wild-type and mutant AMPA GluR2 S1S2
proteins were overexpressed and puriﬁed as in Stoll et al. (2,3,7).
Fluorescence studies
NMDA
Fluorescence was performed on a Proton Technology International ﬂuores-
cence spectrophotometer at a cell temperature of 25C using 4.0-nm
excitation and 1.0-nm emission slit widths. All scans were performed from
285 to 450 nm with a 280-nm excitation in a 3-mm pathlength cell. Each
sample was equilibrated for 60 s at 25C in the sample holder before data
acquisition.
Blanks were measured by adding the appropriate ligand to buffer 3 (10
mM MES, 25 mM NaCl, 1 mM glycine, pH 6.5). Since all blank signals
were,1% of the total ﬂuorescence signal at 325 nm, experimental data was
reported without subtraction of a blank. Protein samples for the EC50 and
competition binding experiments were at a concentration of 3.75 mM, and
for the Stern-Volmer experiments were at a concentration of 3.41 6 0.16
mM in buffer 3. All ligands were solubilized in water. Spermine (Sigma, St.
Louis, MO) and spermidine (Sigma) were diluted to a stock concentration of
100 mM. Zinc acetate (EM Science, Gibbstown, NJ) was diluted to a stock
concentration of 150 mM.
In the EC50 experiments (Table 1 and Fig. 2S in the Supplementary
Material), spermine was added to a ﬁnal concentration of 0.300–50.0 mM
(79.8:1–13,300:1 molar ratio of ligand/protein), spermidine was added to a
ﬁnal concentration of 0.250–50.0 mM (66.5:1–13,300:1 molar ratio ligand/
protein), and zinc acetate was added to a ﬁnal concentration of 2.0–75.0 mM
(320:1–12,000:1 molar ratio ligand/protein). For determination of the EC50,
percent binding was deﬁned as [(ﬂuorescence emission in the absence of
ligand at 325 nm – ﬂuorescence emission in the presence of a certain con-
centration of ligand at 325 nm) / (ﬂuorescence emission in the absence of
ligand at 325 nm – ﬂuorescence emission in the presence of a saturating
concentration of the ligand at 325 nm)] 3 100. Saturating concentrations
were determined to be 75 mM zinc acetate (20,000:1 molar ratio ligand/
protein), 50 mM spermine (13,000:1 molar ratio ligand/protein), and 35 mM
spermidine (9300:1 molar ratio ligand/protein).
For competition studies (Table 3) the sample was allowed to equilibrate
for 30 s after the addition of the ﬁrst ligand and an additional 30 s after ad-
dition of the second ligand before data was collected. Percent quenching was
deﬁned as [(ﬂuorescence emission in the absence of the ligand at 325 nm 
ﬂuorescence emission in the presence of the ligand at 325 nm)/ﬂuorescence
emission in the absence of the ligand at 325 nm] 3100.
In the Stern-Volmer experiments (Table 4 and Fig. 4S in the Supple-
mentary Material), potassium iodide (EM Science) ranging in concentration
from 25 to 400 mM was added to 3.41 6 0.16 mM NMDA NR1-1b-S1S2
that had been mixed with ligand at a ﬁnal concentration of 0.5 mM spermine,
0.8 mM spermidine, or 5 mM Zn (II). Data was analyzed using the Stern-
Volmer equation F0/F ¼ 1 1 KSV[Q], where the Stern-Volmer constant
KSV ¼ kqt0. The values F0 and F are the ﬂuorescence intensities in the ab-
sence and in the presence of quencher, respectively, [Q] is the concentration
of quencher, kq is the biomolecular collisional constant, and t0 is the lifetime
of the ﬂuorophore in the absence of quencher. Since it is assumed that the
lifetime, t0, does not change after ligand binding, KSV can be used as a
measure of the biomolecular collisional constant and therefore reﬂects the
change in accessibility of the tryptophan residues to quencher upon ligand
binding (29,30). Data corresponding to at least six different iodide concen-
trations were used to construct each Stern-Volmer plot.
Each data set consists of emission spectra from independent scans of at
least four identically prepared samples. The average spectrum of each data
set was calculated by averaging the intensity at individual wavelengths be-
tween 285 and 450 nm. The standard deviation (SD) was calculated at 325
nm for each data set based on the four data points for each protein-ligand
mixture, and the error at the 95% conﬁdence interval was determined. The
95% conﬁdence interval (m) was deﬁned as (t * SD)/(number of data
points)1/2, where t is the Student’s t value for the appropriate degrees of
freedom at the 95% conﬁdence level.
AMPA
Fluorescence studies were performed at 25C using 2.5 nm excitation and
emission slit widths. All emission scans were performed from 285 to 450 nm
with a 280 nm excitation in a 3-mm path length cell. Each sample was
equilibrated for 30 s at 25C in the sample holder before data acquisition.
Blank samples of buffer 9 (650 mM arginine-HCl, 400 mM KCl, 10 mM
NaCl, 1 mM EDTA, pH 8.5) were analyzed and were shown to contribute
,1% to the total ﬂuorescence signal at 340 nm, and therefore, experimental
data was reported without subtraction of a blank. Protein samples were at a
concentration of 5.2 mM in buffer 9. Neurosteroids (PS, Sigma; and PregaS,
Steraloids, Newport, RI) were solubilized in 100% methanol to a stock
concentration of 15 mM. To take into account any effects methanol had on
the ﬂuorescence emission spectrum of the GluR2-S1S2 domain, ﬂuores-
cence emission in the absence of quencher was determined in the presence of
the ﬁnal concentration of methanol, thus allowing for a direct comparison
between samples with and without neurosteroid. Final methanol concentra-
tions up to 6.0% were determined to be acceptable (6).
To construct a Stern-Volmer plot (Table 2 and Fig. 3S in the Supple-
mentary Material), acrylamide (Sigma) ranging in concentration from 39 to
280 mMwas added to 5.2 mMGluR2-S1S2 that had been mixed with ligand
at a ﬁnal concentration of 308 mMPS or 308 mMPregaS. Data was analyzed
as described above for NMDA NR1-1b S1S2.
Each data set consisted of emission spectra from independent scans of at
least three identically prepared samples. The standard deviation (SD) of the
intensity at 340 nm was calculated for each data set based on the three data
points for each protein-ligand mixture, and the error at the 95% conﬁdence
interval was determined as described above.
TABLE 1 Ligand binding afﬁnity to NMDA NR1-1b and AMPA
GluR2 S1S2 domains
NMDA S1S2, EC50 GluR2 S1S2, EC50
PS ND* 316 mMy
PregaS ND* 327 mMz
Spermine 1649 6 135 mM ND*
Spermidine 1052 6 136 mM ND*
Zinc acetate 13.5 6 1.2 mM ND*
In each NMDA NR1-1b S1S2 experiment, the ﬂuorescence emission at 325
nm of 3.75 mM NMDA NR1-1b S1S2 in buffer 3 was probed. Ligands
were used in the following ﬁnal concentrations: 2–75.0 mM zinc acetate
(320:1–12,000:1 molar ratio ligand/protein), 0.250–50.0 mM spermidine
(66.5:1–13,300:1 molar ratio ligand/protein), and 0.300–50.0 mM spermine
(79.8:1–13,300:1 molar ratio of ligand/protein). In each GluR2 S1S2
experiment, the ﬂuorescence emission at 340 nm of 7.1 mM GluR2 S1S2 in
buffer 9 was probed. Ligands were used in the following ﬁnal concentra-
tions: 25–1030 mM PS or PregaS (3.5:1–145:1 molar ratio of ligand/
protein). EC50 was determined from a plot of % bound versus log [ligand].
Error is reported at the 95% conﬁdence level.
*No binding detected.
yError estimated as 69.1 mM (6).
zError estimated as 67.0 mM (6).
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RESULTS AND DISCUSSION
PS and PregaS bind to the AMPA GluR2 S1S2
domain, but not to the NMDA NR1-1b S1S2 domain
Intrinsic tryptophan ﬂuorescence emission spectroscopy was
employed to monitor the binding of PS and PregaS to the
GluR2 S1S2 domain (four tryptophans: Trp-460, -671, -766,
-767) and the NMDA NR1-1b S1S2 domain (four trypto-
phans: Trp-498, -731, -768, -792) (Fig. 1S:B-E in the
Supplementary Material). We have previously shown (Table
1 and Fig. 2S:A in the Supplementary Material) that the
GluR2 S1S2 domain binds with approximate equal afﬁnity
to both PS (EC50: 316 mM) and PregaS (EC50: 327 mM)
(6,7). Here we report that neither sulfated neurosteroid binds
to the NMDA NR1-1b S1S2 domain. This latter result is
consistent with the observation that whether PS activates or
inhibits the NMDA receptor depends upon the NR2 subunit
composition, with NR1-NR2A/NR2B combinations being
activated by PS and NR1-NR2C/NR2D combinations being
inhibited by PS (31). In addition, it is in agreement with a
proposed steroid modulatory domain for PS containing part
of the NR2B subunit (8).
Although it has been proposed from electrophysiology
studies that PS and PregaS bind to two independent extra-
cellular binding sites on the NMDA receptor, the location of
the extracellular binding sites have not been deﬁned, nor has
the existence of independent binding sites been shown for
other iGluRs (32). To explore the latter, a Stern-Volmer anal-
ysis was completed for both the wt and three tryptophan
mutants (W460F, W671F, W766/767F) of the GluR2 S1S2
domain (Table 2 and Fig. 3S in the Supplementary Material).
These experiments probe the ability of acrylamide to access
the tryptophan residues of the GluR2 S1S2 domain and
quench their ﬂuorescence emission—with an increase in Ksv
corresponding to an increase in the bimolecular collisional
constant and an increase in accessibility (29,30). Within the
95% conﬁdence intervals calculated, this Stern-Volmer anal-
ysis did not allow for a differentiation of the conformational
changes that take place upon binding of each neurosteroid to
the GluR2 S1S2 domain.
The polyamines spermine and spermidine bind to
the NMDA NR1-1b S1S2 domain, but not to the AMPA
GluR2 S1S2 domain
Spermine was found to bind to the glycine-bound NMDA
NR1-1b S1S2 domain with an EC50 of 1649 6 135 mM,
while spermidine was found to bind with an EC50 of 10526
136 mM (Table 1 and Fig. 2S:C-D in the Supplementary
Material). Neither were found to bind to the GluR2 S1S2
domain (in the presence or absence of glutamate) at concen-
trations up to 2.1 mM. Competition binding assays (Table 3)
show that spermine, spermidine, and Zn(II) all have over-
lapping binding sites in the NMDA NR1-1b S1S2 domain.
For example, upon binding spermidine, the solo quenching
of 34.1 6 5.5% resulting from spermine binding is dimin-
ished to 3.4 6 5.6% and the solo quenching of 41.8 6 6.6%
resulting from Zn(II) binding is diminished to 16.7 6
6.9%. In an effort to differentiate the nature of the confor-
mational change to the NMDA NR1-1b S1S2 domain upon
binding to each of the polyamines, a Stern-Volmer analysis
was performed (Table 4 and Fig. 4S:B-C in the Supplemen-
tary Material). The Stern-Volmer constant for iodide quench-
ing of the apo S1S2 domain was determined to be 2.52 6
0.09 M1, while iodide quenchings of the spermine-bound
and spermidine-bound S1S2 domains were determined to be
1.31 6 0.05 M1 and 1.36 6 0.05 M1, respectively. This
indicates that upon binding of either of the polyamines to the
NR1-1b S1S2 domain, the conformational change that
ensues places the tryptophan residues that are quenched by
iodide in less accessible locations. Neither the Ksv values nor
the competition binding assays allow differentiation of the
binding regions or the induced conformational changes of
TABLE 2 Stern Volmer constants (Ksv) of acrylamide
accessibility of wt and mutant GluR2 S1S2 tryptophan residues
Apo (M1) PS (M1) PregaS (M1)
wt 6.29 6 0.22 6.65 6 0.19 6.67 6 0.54
W460F 5.44 6 0.26 5.84 6 0.28 5.28 6 0.17
W671F 5.80 6 0.15 6.31 6 0.29 5.92 6 0.12
W766/767F 6.36 6 0.17 4.82 6 0.25 4.88 6 0.19
Acrylamide ranging in concentration from 39 to 280 mM was added to 5.2
mM GluR2 S1S2 mixed with ligand that was at a ﬁnal concentration of 308
mM PS or PregaS, and the ﬂuorescence emission at 340 nm was probed.
Data was analyzed using the Stern-Volmer equation F0/F ¼ 1 1 KSV[Q].
Error is reported at the 95% conﬁdence level.
TABLE 3 Competition binding studies of the NMDA NR1-1b S1S2 domain
First ligand added Average (%) quenching Second ligand added Total (%) quenching Quenching (%) due to second ligand
Zinc acetate 41.8 6 6.6 Spermidine 47.3 6 3.9 5.5 6 7.7
Spermine 49.1 6 4.2 7.3 6 7.8
Spermidine 55.0 6 4.1 Zinc acetate 38.3 6 5.5 16.7 6 6.9
Spermine 58.4 6 3.8 3.4 6 5.6
Spermine 34.1 6 5.5 Zinc acetate 44.9 6 4.9 15.8 6 7.4
Spermidine 57.5 6 4.1 23.4 6 6.9
The ﬂuorescence emission at 325 nm of 3.75 mM NMDA NR1-1b S1S2 in buffer 3 was probed. Ligands were used in the following ﬁnal concentrations: 33
mM zinc acetate, 1.3 mM spermidine, and 833 mM spermine. Error is reported at the 95% conﬁdence level.
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spermine and spermidine upon binding to the NMDA NR1-
1b S1S2 domain.
It has been suggested that the polyamines, whose biosyn-
thesis is under tight and highly regulated control, appear to
be well suited for regulation of iGluRs (19). Although not
normally found in the synaptic cleft, under certain conditions
polyamine synthesis is upregulated and polyamines are re-
leased into the synaptic cleft where they can interact with the
extracellular surface of iGluRs (33–36). Although the bind-
ing afﬁnities determined for these polyamines (EC50s of
1649 and 1052 mM) are not tight, it has been estimated that
in proliferating cells as well as mature secretory cells that
cytosolic concentrations of spermine and spermidine are at
the mM level (33,34). This data is the ﬁrst report of poly-
amine binding to the S1S2 domain of an iGluR, and in par-
ticular an NMDA NR1b S1S2 domain, extending the list of
possible extracellular binding sites.
Zn(II) binds to the NMDA NR1-1b S1S2 domain, but
not to the AMPA GluR2 S1S2 domain
Zn(II) was found to bind to the glycine-bound NMDA NR1-
1b S1S2 domain with an EC50 of 13.5 6 1.2 mM (Table 1
and Fig. 2S:B in the Supplementary Material). It was not,
however, found to bind to the GluR2 S1S2 domain (in the
presence or absence of glutamate) at concentrations up to
21 mM. Competition binding assays (Table 3) show that the
Zn(II) binding site on the NR1-1b S1S2 domain overlaps
with that of both spermine and spermidine. Upon binding of
Zn(II), the solo quenching of 34.1 6 5.5% resulting from
binding of spermine is decreased to 7.3 6 7.8% and the
solo quenching of 55.0 6 4.1% resulting from binding of
spermidine is decreased to 5.5 6 7.7%. This overlap sup-
ports the concept of partial overlapping binding sites or com-
mon downstream targets, which have been proposed (9). The
results presented here localize at least one possible over-
lapping binding site to the S1S2 domain of the NMDA
NR1-1b subunit. A Stern-Volmer analysis was performed to
differentiate the conformational change induced upon Zn(II)
binding from that of polyamine binding (Table 4 and Fig.
4S:A in the Supplementary Material). The Stern-Volmer
constant for iodide quenching of the apo S1S2 domain was
determined to be 2.526 0.09 M1, while those of spermine-
bound, spermidine-bound, and Zn(II)-bound S1S2 domains
were determined to be 1.31 6 0.05 M1, 1.36 6 0.05 M1,
and 9.336 0.15 M1, respectively. This indicates that while
binding of either of the polyamines to the NR1-1b S1S2 do-
main causes a conformational change that places the trypto-
phan residues that are quenched by iodide in less accessible
locations, the conformational change upon Zn(II) binding
places them in more accessible regions. Since iodide is an
external quencher, this would suggest a more solvent-exposed
and more polar location for the tryptophan residues that are
quenched by iodide upon Zn(II) binding of the NMDA NR1-
1b S1S2 domain. This idea is further supported by the data
in Table 5 (and Fig. 1S:A in the Supplementary Material)
showing the maximum wavelength of emission of both the
apo and ligand bound NMDA NR1-1b S1S2 domains. As
can be seen, the maximum emission is red-shifted by;8 nm
from 326 to 334 nm upon Zn(II) binding, supporting a con-
formational change that places at least some of the trypto-
phan residues in a more polar environment.
To our knowledge, this is the ﬁrst report of a low afﬁnity
Zn(II) binding site in the S1S2 domain of any iGluR.
Summary
Although the S1S2 domains from the NMDA NR1-1b sub-
unit and the AMPA GluR2 subunit are 33% identical (54%
homologous) at the primary amino-acid level and have simi-
lar tertiary structures (Fig. 2) (1,4), they have been shown
here to bind to different endogenous modulators. It is in-
teresting to speculate that this difference in ability to be
modulated correlates with difference in function, as AMPA
receptors mediate fast depolarization while NMDA receptors
mediate the slower component of the excitatory postsynaptic
potential. Of particular signiﬁcance are two ﬁndings. The
ﬁrst is that while PS and PregaS bind to the S1S2 domain of
the GluR2 subunit, neither binds to the S1S2 region of the
NR1-1b subunit. Since it is known that both PS and PregaS
modulate the activity of the NMDA receptor from the extra-
cellular face (32), this leaves the possibility of its binding to
either an extracellular region on the NR2 subunit or an ex-
tracellular interface between the NR1 and NR2 subunits.
The second is that the polyamines spermine and spermidine
as well as Zn(II) bind to the S1S2 domain of the NR1-1b
TABLE 4 Stern Volmer constants (Ksv) of iodide accessibility
to NMDA NR1-1b S1S2 domain tryptophan residues
Apo
(M1)
Spermine
(M1)
Spermidine
(M1)
Zinc acetate
(M1)
NMDA S1S2 2.52 6 0.09 1.31 6 0.05 1.36 6 0.05 9.33 6 0.15
Iodide ranging in concentration from 25 to 400 mM was added to 3.41 6
0.16 mM NMDA NR1-1b S1S2 mixed with ligand at a ﬁnal concentration
of 0.5 M spermine, 0.8 M spermidine, or 5 M Zn (II) and the ﬂuorescence
emission at 325 nm was probed. Data was analyzed using the Stern-Volmer
equation F0/F ¼ 11 KSV[Q]. Error is reported at the 95% conﬁdence level.
TABLE 5 Maximum wavelength of emission of the apo and
ligand bound NMDA NR1-1b S1S2 domain
Ligand Maximum wavelength (nm)
Apo 326 6 3
Spermidine 325 6 3
Spermine 324 6 2
Zinc acetate 334 6 2
The ﬂuorescence emission at 325 nm of 3.75 mM NMDA NR1-1b S1S2 in
buffer 3 was probed. Ligands were used in the following ﬁnal concentra-
tions: 75 mM zinc acetate, 2 mM spermidine, and 1 mM spermine.
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subunit, but not to the S1S2 domain of the GluR2 subunit.
While the binding site for all three of these modulators over-
laps, the conformational change caused by Zn(II) binding is
distinct. These ﬁndings are important, as they locate pre-
viously unidentiﬁed distinct subunit domains to which each
of these modulatory ligands bind. Understanding speciﬁc
ligand-receptor binding interactions and the nature of the
resultant conformational change has potential for the rational
design of therapeutics to be used against diseases caused by
iGluR misregulation.
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